Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases
- 31 December 1994
- journal article
- clinical trial
- Published by Elsevier
- Vol. 30 (1) , 103-105
- https://doi.org/10.1016/s0959-8049(05)80028-0
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Biodistribution of lymphokine‐activated killer (LAK) cells in WAG rats after hepatic‐artery or jugular‐vein infusionInternational Journal of Cancer, 1992
- Regional administration of lymphokine-activated killer cells can be superior to intravenous applicationCancer, 1992
- Preferential Localization of Human Adherent Lymphokine-Activated Killer Cells in Tumor MicrocirculationJNCI Journal of the National Cancer Institute, 1991
- Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastases.Journal of Clinical Oncology, 1990
- Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer PatientsAnnals of Surgery, 1989
- Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer CellsAnnals of Internal Medicine, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2Science, 1984